FATE Fate Therapeutics Inc

Price (delayed)

$71.66

Market cap

$6.82B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.35

Enterprise value

$6.84B

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture ...

Highlights
FATE's revenue is up by 20% since the previous quarter
The gross profit has increased by 20% since the previous quarter
The company's equity has surged by 59% YoY but it fell by 4.8% QoQ
The net income has plunged by 82% YoY and by 15% from the previous quarter
FATE's EPS is down by 50% year-on-year and by 11% since the previous quarter

Key stats

What are the main financial stats of FATE
Market
Shares outstanding
95.18M
Market cap
$6.82B
Enterprise value
$6.84B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.96
Price to sales (P/S)
140.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
142.47
Earnings
Revenue
$48.01M
EBIT
-$212.02M
EBITDA
-$208.26M
Free cash flow
-$131.43M
Per share
EPS
-$2.35
Free cash flow per share
-$1.39
Book value per share
$8
Revenue per share
$0.51
TBVPS
$10.77
Balance sheet
Total assets
$1.02B
Total liabilities
$263.6M
Debt
$110.47M
Equity
$752.07M
Working capital
$607.67M
Liquidity
Debt to equity
0.15
Current ratio
6.75
Quick ratio
6.83
Net debt/EBITDA
-0.09
Margins
EBITDA margin
-433.8%
Gross margin
100%
Net margin
-441.6%
Operating margin
-328.9%
Efficiency
Return on assets
-25.6%
Return on equity
-36.1%
Return on invested capital
-32.4%
Return on capital employed
-23.3%
Return on sales
-441.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FATE stock price

How has the Fate Therapeutics stock price performed over time
Intraday
7.74%
1 week
4.72%
1 month
-15.14%
1 year
94.15%
YTD
-21.19%
QTD
-17.43%

Financial performance

How have Fate Therapeutics's revenue and profit performed over time
Revenue
$48.01M
Gross profit
$48.01M
Operating income
-$157.88M
Net income
-$212.02M
Gross margin
100%
Net margin
-441.6%
The net income has plunged by 82% YoY and by 15% from the previous quarter
The operating margin has soared by 64% YoY and by 6% from the previous quarter
The net margin rose by 50% year-on-year and by 4.4% since the previous quarter
FATE's operating income is down by 32% year-on-year and by 13% since the previous quarter

Growth

What is Fate Therapeutics's growth rate over time

Valuation

What is Fate Therapeutics stock price valuation
P/E
N/A
P/B
8.96
P/S
140.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
142.47
FATE's EPS is down by 50% year-on-year and by 11% since the previous quarter
The company's equity has surged by 59% YoY but it fell by 4.8% QoQ
FATE's price to book (P/B) is 33% lower than its last 4 quarters average of 12.4 but 21% higher than its 5-year quarterly average of 6.9
The stock's price to sales (P/S) is 34% less than its last 4 quarters average of 197.6
FATE's revenue is up by 20% since the previous quarter

Efficiency

How efficient is Fate Therapeutics business performance
FATE's return on sales is up by 50% year-on-year and by 4.4% since the previous quarter
The ROIC has grown by 43% YoY and by 16% from the previous quarter
Fate Therapeutics's return on assets has increased by 11% YoY
The ROE has grown by 6% YoY

Dividends

What is FATE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FATE.

Financial health

How did Fate Therapeutics financials performed over time
FATE's total assets has surged by 55% year-on-year but it is down by 2.9% since the previous quarter
The total liabilities has grown by 47% YoY and by 3% from the previous quarter
The debt is 85% smaller than the equity
The company's equity has surged by 59% YoY but it fell by 4.8% QoQ
The debt rose by 36% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.